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Inefficient adenoviral vector (AdV)-mediated gene transfer to the ciliated respiratory epithelium has hin-
dered gene transfer strategies for the treatment of cystic fibrosis lung disease. In part, the inefficiency is due
to an absence of the coxsackie B and adenovirus type 2 and 5 receptor (CAR) from the apical membranes of
polarized epithelia. In this study, using an in vitro model of human ciliated airway epithelium, we show that
providing a glycosylphosphatidylinositol (GPI)-linked AdV receptor (GPI-CAR) at the apical surface did not
significantly improve AdV gene transfer efficiency because the lumenal surface glycocalyx limited the access of
AdV to apical GPI-CAR. The highly glycosylated tethered mucins were considered to be significant glycocalyx
components that restricted AdV access because proteolytic digestion and inhibitors of O-linked glycosylation
enhanced AdV gene transfer. To determine whether these in vitro observations are relevant to the in vivo
situation, we generated transgenic mice expressing GPI-CAR at the surface of the airway epithelium, crossbred
these mice with mice that were genetically devoid of tethered mucin type 1 (Muc1), and tested the efficiency of
gene transfer to murine airways expressing apical GPI-human CAR (GPI-hCAR) in the presence and absence
of Muc1. We determined that AdV gene transfer to the murine airway epithelium was inefficient even in
GPI-hCAR transgenic mice but that the gene transfer efficiency improved in the absence of Muc1. However, the
inability to achieve a high gene transfer efficiency, even in mice with a deletion of Muc1, suggested that other
glycocalyx components, possibly other tethered mucin types, also provide a significant barrier to AdV inter-
acting with the airway lumenal surface.
Replication-deficient adenoviral vectors (AdV) based on se-
rotypes 2 and 5 have been shown to efficiently transduce non-
polarized human airway epithelial cells in vitro. However,
these vectors have failed to efficiently transfer transgenes to
the human differentiated mucociliary respiratory epithelium
after intralumenal delivery in vitro and in vivo (26, 28, 36, 46,
47). For cystic fibrosis (CF) lung gene therapy, the target
airway epithelial cells requiring expression of a functional CF
transmembrane conductance regulator (CFTR) are considered
the ciliated airway epithelial cells (7). Clinical and preclinical
studies of AdV-mediated gene transfer to the lung epithelium
have concluded that the numbers of epithelial cells expressing
the corrective transgene, CFTR, have been low and insufficient
for correction of the CF ion transport defect in the lungs (19,
21). In addition, immune responses to expressed viral genes
and/or transgenes combined with the involvement of inflam-
matory cells such as macrophages limit the level and duration
of transgene expression by AdV (11, 33, 42, 43, 49). These
observations have limited the utility of AdV-based gene trans-
fer strategies for CF lung disease.
Inefficient AdV-mediated gene transfer via the lumenal sur-
faces of polarized epithelial cells has been reported to be due
to the absence of apical receptors which are required for Ad
entry (28, 36). The attachment receptor for human Ad from
subgroups A, C, D, E, and F is the coxsackie B and adenovirus
type 2 and 5 receptor (CAR) (4, 32). Cell lines that are nor-
mally resistant to Ad infection with these serotypes become
permissive for infection when transfected with human CAR
(hCAR), suggesting that hCAR alone is sufficient to mediate
the entry of Ad into cells (4, 27, 32, 37). Most polarized epi-
thelial cells, including human columnar airway epithelial cells,
express hCAR at the basolateral surface, with undetectable
hCAR at the apical surface (28, 36). The localization of hCAR
to regions associated with tight junctional complexes and the
suggestion that hCAR-hCAR interactions may be an impor-
tant mechanism of cell-cell adhesion in these regions have led
to the speculation that the natural spread of Ad infection in the
lung may involve a disruption of hCAR-mediated cell adhesion
(15, 35). In contrast to columnar cells, airway epithelial basal
cell types express hCAR with a nonpolarized distribution and
are efficiently infected by AdV delivered to the basolateral
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compartments of human polarized airway epithelial cell cul-
tures (28, 48).
Several strategies to retarget AdV to receptors present on
the airway surface have been attempted to improve gene trans-
fer efficiency to the respiratory epithelium. Although targeted
vectors have shown promise with nonpolarized cell lines ex-
pressing target receptors, only modest improvements in gene
transfer efficiency to well-differentiated respiratory epithelia
have been reported (18, 22). The feasibility of targeting AdV to
the apical surfaces of polarized epithelia was previously tested
by redirecting hCAR to the apical membrane by engineering
the external domain of hCAR (containing the Ad binding
domain) to the glycosylphosphatidylinositol (GPI) linker re-
gion of CD55, generating a GPI-hCAR chimera (27, 37). On
nonpolarized cells, hCAR and GPI-hCAR are equally efficient
at mediating AdV attachment and entry (27, 37). Although the
transfection of GPI-hCAR into polarized MDCK cells led to
an apical distribution of GPI-hCAR, a significant enhancement
of AdV-mediated gene transfer after apical inoculation was
not observed. However, increased AdV access to GPI-hCAR
and a significant improvement in gene transfer efficiency were
achieved after neuraminidase (NA) treatment of the apical
surfaces of MDCK-GPI-hCAR cells, suggesting that apical
surface sialic acid residues contained within the glycocalyx
layer of MDCK cells restricted AdV access to GPI-hCAR (27).
In contrast, in an in vitro model of human differentiated airway
epithelium, apical GPI-hCAR expression was sufficient to me-
diate efficient gene transfer, and the access of AdV to apical
GPI-hCAR was unhindered by glycocalyx components (37).
To resolve these discrepancies, in addition to expressing
GPI-hCAR in an in vitro model of human tracheobronchial
airway epithelium (HAE) that recapitulates the polarized,
pseudostratified mucociliary epithelium present in human car-
tilaginous airways in vivo, we also generated transgenic mice
expressing GPI-hCAR with an epithelial cell-specific distribu-
tion and used this model to determine if AdV-mediated gene
transfer efficiency is enhanced by the presence of an apical
AdV receptor in the murine airway epithelium in vivo. Since
previous studies have shown that transfection of the large,
heavily glycosylated tethered mucin MUC1 into nonpolarized
human airway epithelial cells or MDCK cells reduces AdV-
mediated gene transfer efficiency (1), we also used a combina-
tion of Muc1 knockout (30) and GPI-hCAR transgenic mouse
models to determine the role of this specific mucin on AdV
access to apical GPI-hCAR in vivo.
MATERIALS AND METHODS
Cell culture. Human airway tracheobronchial epithelial cells were obtained
from airway specimens that were resected during lung transplantation according
to UNC Institutional Review Board (IRB)-approved protocols by the UNC CF
Center Tissue Culture Core and then cultured as previously described (28).
Briefly, primary cells derived from single patient sources were expanded on
plastic to generate passage 1 (P1) cells and were plated at a density of 250,000
cells per well on permeable Transwell-Col (T-Col; 12-mm diameter) supports.
HAE cultures were grown with an air-liquid interface for 4 to 6 weeks to
generate well-differentiated, polarized cultures that resembled in vivo pseudo-
stratified mucociliary epithelium.
For the generation of HAE cultures expressing GPI-hCAR (GPI-hCAR
HAE), the apical surfaces were exposed to sodium caprate (30 mM in tissue
culture medium for 3 min to transiently open epithelial cell tight junctions and
expose basolateral surfaces to facilitate AdV uptake), rinsed three times with
phosphate-buffered saline (PBS), and then inoculated with AdV expressing GPI-
hCAR (AdVgpi-hCAR; 2  1010 particles/ml in 0.3 ml of medium for 4 h at
37°C). Forty-eight hours later, GPI-hCAR was assessed by immunofluorescence
by incubating the lumenal surfaces of HAE cells with an anti-human CAR
monoclonal mouse antibody (RmcB) followed by anti-mouse immunoglobulin G
(IgG)-Texas Red. Fluorescence microscopy was performed en face with a Leica
Leitz DMIRB inverted fluorescence microscope equipped with a cooled color
charge-coupled device digital camera (Q-Imaging; MicroPublisher). Confocal
XZ optical sectioning was performed with a laser scanning confocal microscope
(Leica TCS). For immunogold localization, identical procedures were performed
except that goat anti-mouse IgG conjugated to 12-nm-diameter colloidal gold
particles was use as the secondary antibody (Jackson Labs). Colloidal gold was
visualized by standard transmission electron microscopy.
Adenoviral vectors. Adenoviral vectors containing the green fluorescent pro-
tein (GFP) gene (AdVGFP), the -galactosidase (LacZ) gene (AdVLacZ), and
the GPI-hCAR chimeric gene (AdVgpi-hCAR) under the control of a cytomeg-
alovirus promoter were all produced by the UNC Gene Therapy Center Vector
Core. The GPI-hCAR construct was generated as previously described (27).
Generation of mouse models. Transgenic mice were generated and utilized
with approval from the UNC Institutional Animal Care and Use Committee. For
epithelial cell-specific expression, the K18 promoter element from plasmid
K18mTELacZ (a kind gift from Jim Hu [12, 13]), which was shown to direct
epithelial cell-specific expression in transgenic mice, was fused to the GPI-hCAR
sequence by a PCR-based cloning strategy (details available upon request). The
polyadenylation signal was originally derived from pEGFP-C1 (Clontech). Al-
though the K18 promoter element was shown to direct expression to the epithe-
lium in transgenic mice, there was a vast difference from founder line to founder
line in previous reports, suggesting that this promoter is subject to positional
effects (12, 13). In order to reduce the likelihood of positional effects and to
increase the chances of obtaining the desired expression pattern, we used insu-
lator elements from the chicken -actin gene (a kind gift from Gary Felsenfeld
[14, 39]), which have been shown to reduce positional effects in transgenic
models, to flank the entire expression cassette. Pronuclear injections of a trans-
genic construct containing the insulator elements, the K18 epithelial cell-specific
promoter, and the GPI-hCAR sequence into C57BL/6J  C3H mouse strain
blastocysts were performed in the UNC Transgenic Core Facility according to
established protocols. Founder animals that transmitted GPI-hCAR to their
progeny were identified by Southern blotting (not shown), and progeny mice
(identified by PCR; details available upon request) were evaluated for the ex-
pression of GPI-hCAR.
For immunolocalization of GPI-hCAR in murine tissue, tissues were fixed in
Omnifix II (FR Chemicals, Albany, N.Y.), and sections of paraffin-embedded
tissues were prepared. After rehydration, tissue sections were probed with an
anti-human CAR antibody (RmcB) followed by goat anti-mouse IgG conjugated
to fluorescein isothiocyanate (Jackson Labs). Muc1 immunolocalization was
performed as described above except that tissues were incubated with an Arme-
nian hamster monoclonal anti-Muc1 antibody (CT2) (17) followed by goat anti-
Armenian hamster IgG conjugated to Texas Red (Jackson Labs). For immuno-
gold detection in murine tracheas, isolated tracheas were incubated with RmcB
followed by goat anti-mouse IgG conjugated to 12-nm-diameter colloidal gold
particles. The investigator performing the immunolocalization was blinded to the
genotypes of the animals under study.
Assessment of gene transfer. For assessments of AdV-mediated gene transfer
to HAE and GPI-hCAR HAE, 72 h after sodium caprate or sodium caprate-
AdVgpihCAR inoculation the lumenal surfaces of the cultures were rinsed with
PBS and inoculated with AdVGFP or AdVLacZ (2  1010 particles/ml in 0.3 ml
of medium for 2 h at 37°C; 4  104 particles per cell [PPC], unless otherwise
stated). Forty-eight hours later, the gene transfer efficiency was assessed either by
image analyses of GFP expression that quantitated the percentage of apical
surface area expressing the transgene or by standard enzyme assays for AdV-
LacZ as described previously (28, 48).
Delivery of AdV to the murine tracheal epithelium was performed with anes-
thetized animals in which a double tracheostomy was performed between the
third and sixth tracheal cartilage rings. This technique allowed for the animals to
breathe spontaneously through the distal tracheostomy while AdVLacZ was
delivered by a catheter through the proximal tracheostomy. AdVLacZ (20 l of
1011 particles/ml; 4  104 PPC) was delivered with direct visualization to the
region of the murine tracheal epithelium in between the tracheostomies (0.1
cm2 of epithelial surface area) and was maintained for a 30-min incubation. For
experiments with sodium caprate pretreatment, the murine tracheal epithelium
was instilled with sodium caprate (25 mM for 5 min) and the tracheal lumens
were rinsed with PBS immediately prior to AdVLacZ inoculation. All procedures
were performed according to protocols approved by the UNC Institutional An-
imal Care and Use Committee. Forty-eight hours after AdVLacZ inoculation,
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the tracheas were removed, dissected longitudinally, and stained for LacZ ex-
pression by standard X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)
procedures as described previously (26). Digital images of the stained tracheas
were obtained, and the percentages of epithelial surface area that were positive
for transgene expression were determined by digital morphometry (Adobe Pho-
toshop) of the tracheal epithelial surface. For all experiments, the investigators
performing the inoculations and/or digital morphometry were blinded to the
genotypes of the animals until after data analyses were performed. Statistics were
performed with Student’s t test by the use of SigmaStat software.
Detection of apical surface glycocalyx components. Identifications of glycoca-
lyx components were performed with three or more different patient sources of
cells, but estimates of relative amounts of particular antigens were compared for
a single patient source. Lectin and antibody detection techniques were used to
determine the absence or presence of the following specific moieties: 2-3-linked
sialic acid residues (MAL II lectin; Vector Labs), 2-6-linked sialic acid residues
(SNA lectin; Vector Labs), MUC1 (b2729 antibody; a gift from Fujirebio Diag-
nostics Inc.), heparan sulfate (F58-10E4, F69-3G10, or HepSS-1 antibody; Seika-
gaku), chondroitin-4-sulfate and chondrotin-6-sulfate (MC21C and LY11 anti-
bodies, respectively; Seikagaku), and keratan sulfate (5D4 antibody; Seikagaku).
Lectins and primary antibodies were incubated with the apical surfaces of live or
paraformaldehyde-fixed HAE followed by incubation with secondary reagents
conjugated to Cy3 or Texas Red.
RT-PCR for mucin gene expression. The expression of a variety of reported
transmembrane mucins was determined for human and mouse airway tissues by
reverse transcription-PCR (RT-PCR) analysis. For all mucins, primers were
designed from National Center for Biotechnology Information accession num-
bers (reference sequence numbers when available) to span at least one intron
(primers and accession numbers are available upon request). Based upon ex-
pression information in Unigene (National Center for Biotechnology Informa-
tion), all reported transmembrane mucins are expressed in the placenta and/or
the colon, so these two tissues were chosen as positive controls (human colon and
placental RNAs were purchased from Ambion; mouse colon RNAs were isolated
in-house). Human primary bronchial RNAs were isolated from HAE and nasal
RNAs were isolated from epithelial cells obtained via nasal scrape biopsies
according to established IRB-approved protocols. Mouse tracheal and lung
RNAs were isolated from dissected mouse tissues. RNAs from all samples
prepared in-house were purified by the use of RNeasy RNA Mini isolation kits
(Qiagen) followed by DNase digestion (Qiagen). Two hundred nanograms of
total RNA was reverse transcribed to cDNA by the use of random primers and
SuperScript II reverse transcriptase (Invitrogen). PCRs were performed with
AmpliTaq Gold Taq polymerase (Applied Biosystems) in the buffer supplied by
the manufacturer, with 10 pmol of each primer and 1 l of cDNA, in a total
volume of 50 l. The PCR conditions were 7 min at 94°C followed by 35 cycles
of 94°C for 30 s, 55 to 58°C for 30 s, and 72°C for 1 min. RT-PCR products were
separated by electrophoresis in 1% agarose gels and visualized by ethidium
bromide staining under UV light.
Elimination of glycocalyx structures. The following enzymes were prepared in
serum-free medium and were exposed to the apical surfaces of HAE prior to
AdV inoculation under the indicated conditions: keratanase I and II (0.4 U/ml,
18 h; Seikagaku); O-sialoglycoprotein endopeptidase (120 mg/ml, 2 h; Cedarlane,
Ontario, Canada); bovine testis hyaluronidase (1 mg/ml, 12 h; Worthington
Biochemical Corporation); chondroitinase-4-sulfatase (160 mU/ml, 3 h; Seika-
gaku); chondroitinase ABC (0.5 U/ml, 3 h; Seikagaku); elastase (12 U/ml, 2 h;
Sigma); heparinase I, II, or III (4 mIU/ml, 3 h; Sigma); heparinitinase (4 mIU/ml,
2 h; Sigma); protease XIV (0.01%, 2 h; Sigma); and neuraminidase III (160
mU/ml, 2 h; Sigma).
Metabolic inhibitors and vehicle controls were included in the basolateral
medium 5 days prior to the exposure of HAE to AdVGFP or AdVLacZ. The
following inhibitors were used: 1-deoxynojirimycin (1 mM), N-butyldeoxynojiri-
mycin (1 mM), sodium chlorate (30 mM), and benzyl 2-acetamido-2-deoxy--D-
galactopyranoside (1 mM) (all obtained from Sigma-Aldrich). In preliminary
studies, the expression of AdVgpi-hCAR at the lumenal surface of HAE was not
altered by a 5-day exposure to any of the enzymes or inhibitors used.
Freeze substitution and ruthenium red protocols. Human tracheal segments
obtained according to UNC IRB-approved protocols were prepared for trans-
mission electron microscopy (TEM) by the freeze substitution technique (see
below) and were stored in liquid nitrogen (LN2). Airway epithelial cells were
isolated from the same patient source used for the generation of HAE cultures,
subjected to freeze substitution, and stored in LN2. Tissues and HAE samples
were then processed and analyzed in parallel. For freeze substitution, samples
were immersed in a cold 0.2 M sucrose solution (100 ml of 0.2 M Sorenson’s
buffer, 100 ml of distilled water, and 13.6 g of sucrose) for 1 h at 4°C. The samples
were then immersed in a cold 25% glycerol solution (3.8 ml of 0.2 M Sorenson’s
buffer, 3.8 ml of distilled water, and 2.5 ml of glycerol) for no longer than 1 h,
plunge frozen in Freon, and stored in LN2. The samples were transferred to
cooled 4% osmium tetroxide in acetone, stored at 80°C for 4 days, and then
transferred to 20°C for 2 h, 4°C for 2 h, and room temperature for 1 h. After
an acetone wash, the samples were infiltrated with propylene oxide and embed-
ded in Epon resin for standard TEM processing.
For the visualization of acid mucopolysaccharides of the glycocalyx layer,
samples were immersed in a glutaraldehyde solution (5 ml of 4% glutaraldehyde,
5 ml of 0.2 M cacodylate buffer, and 1,500 ppm of ruthenium red) for 1 h at room
temperature. After being rinsed in 0.2 M cacodylate buffer, the tissues were
immersed in an osmium tetroxide solution (5 ml of 5% osmium tetroxide, 5 ml
of 0.2 M cacodylate buffer, and 5 ml with 1,500 ppm of ruthenium red) for 3 h
at room temperature. After a rinse in 0.2 M cacodylate buffer, standard process-
ing for TEM was performed.
Analyses of glycocalyx abundance by TEM. Three different sections of isolated
murine tracheas were obtained from Muc1/ or Muc1/ animals, and sections
stained with ruthenium red were used to visualize the membrane glycocalyx by
TEM (20). Electron photomicrographs were captured at a magnification of
12,000, and the glycocalyx height associated with either nonciliated or ciliated
membranes was measured via image processing as follows. Each image contain-
ing either a nonciliated or ciliated membrane was scanned into Adobe Photo-
shop, a threshold determination for the image was conducted to outline the
ruthenium red-dense glycocalyx layer, and an “and” Boolean image process was
applied. The depth of the ruthenium red staining was measured in terms of
pixels, averaged, and converted into nanometers. The investigator who per-
formed the analysis was blinded to the genotypes of the samples until after data
analyses, and the number of images assessed for each section from each animal
was 30.
RESULTS
Generation of human airway epithelial cell cultures express-
ing GPI-hCAR. Well-differentiated HAE cultures expressing
GPI-hCAR (GPI-hCAR HAE) were generated by transducing
columnar airway epithelial cells with AdVgpi-hCAR. It was
previously shown that airway columnar cells are resistant to
AdV transduction after inoculation of the lumenal surface (26,
28, 36, 47). We achieved a high level of gene transfer in HAE
cultures by transiently disrupting epithelial cell tight junctions
with sodium caprate (30 mM for 3 min, apical exposure) (16)
to allow the exposure of basolateral endogenous hCAR to
AdVGFP (2  1010 particles/ml for 2 h at 37°C; 4  104
PPC). For HAE cultures that were not treated with sodium
caprate but were inoculated with lumenal AdVGFP, few epi-
thelial cells were positive for GFP (	0.01%) postinoculation
(Fig. 1A, panel i). However, after sodium caprate treatment,
AdVGFP inoculation of the apical surface of HAE resulted
in a significant number of GFP-positive epithelial cells, with
70% of the cells that were exposed to virus expressing GFP
(Fig. 1A, panel ii). Confocal XZ optical sectioning revealed
that cells expressing GFP were columnar and that the majority
of GFP-positive cells also costained with an antibody for a cilial
shaft protein (-tubulin IV), suggesting that ciliated columnar
cells were the predominant cell type transduced by AdVGFP
(Fig. 1A, panel iii). The transduction of only occasional -
tubulin IV-negative columnar cells most likely reflects the pre-
dominance of ciliated cells in this HAE model. Basal cells that
were positive for GFP were rarely detected, even after sodium
caprate treatment.
Identical techniques were used for the inoculation of HAE
with AdVgpi-hCAR. With antibodies to detect GPI-hCAR
expression 48 h after AdVgpi-hCAR inoculation, most cells
(70%) were positive for GPI-hCAR in HAE that was treated
with sodium caprate (Fig. 1A, panel v) but not in HAE that was
not treated with sodium caprate (Fig. 1A, panel iv). Confocal
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XZ optical sectioning determined that the localization of GPI-
hCAR was at the lumenal surface (Fig. 1A, panel vi). Further
analyses of GPI-hCAR localization in HAE by immunogold
TEM detected GPI-hCAR on the lumenal surfaces of ciliated
(Fig. 1B, panel i) and occasionally nonciliated cells (not
shown). In ciliated cells, GPI-hCAR was detected on the cilial
shafts, and to a lesser extent, on microvilli (Fig. 1B, panel ii).
Expression of apical surface GPI-hCAR does not signifi-
cantly enhance gene transfer via the lumenal surface of HAE.
To determine whether the expression of GPI-hCAR at the
lumenal surface was sufficient for AdV-mediated gene trans-
fer, we inoculated the apical surface of HAE (Fig. 2A, panel i)
or GPI-hCAR HAE (Fig. 2A, panel ii) with AdVGFP (2 
1010 particles/ml for 2 h at 37°C; 4  104 PPC) and assessed
GFP expression 48 h later. For HAE, few cells (	0.05%) were
positive for GFP after AdV inoculation, indicating a low gene
transfer efficiency (Fig. 2A, panel iii). The inoculation of GPI-
hCAR HAE with AdVGFP resulted in a modest improvement
in gene transfer efficiency (2% of the cells expressed GFP)
(Fig. 2A, panel iv). However, a comparison of the number of
GFP-positive cells with the number of cells expressing GPI-
hCAR (70%) showed that only 3% of GPI-hCAR-positive
cells were transduced by AdVGFP. These data suggest that
the majority of columnar cells expressing GPI-hCAR at the
apical surface did not interact with AdVGFP in a manner that
was conducive to gene transfer. Quantitative analyses using
AdVLacZ (2  1010 or 2  1011 particles/ml) demonstrated
that at best only a two- to threefold increase in gene transfer
was achieved in the presence of GPI-hCAR, even when high
inocula of AdV were used (Fig. 2B). These data suggest that
AdV was unable to interact with GPI-hCAR localized on the
apical surface or that this receptor was insufficient for mediat-
ing viral penetration into HAE. Since GPI-hCAR and hCAR
were previously shown to mediate AdV-mediated gene trans-
FIG. 1. AdV-mediated expression of GPI-hCAR in HAE and localization of GPI-hCAR to ciliated cell shafts. (A) Representative en face
images of HAE inoculated with AdVGFP (i and ii) or AdVgpi-hCAR (iv and v) without (i and iv) or with (ii and v) disruption of epithelial tight
junctions by sodium caprate, with gene expression being assessed 48 h later. Original magnification, 10. Confocal XZ optical sectioning of HAE
expressing GFP (green) and probed with anti--tubulin IV conjugated to Texas Red (red) indicated that predominately ciliated columnar epithelial
cells were transduced by AdVGFP (iii), and GPI-hCAR expressed in HAE was localized to the apical surface, as detected by anti-hCAR (RmcB)
conjugated to Texas Red (red) (vi). Original magnification, 63. (B) Transmission electron micrographs of HAE inoculated with AdV-gpi-hCAR
and probed with RmcB conjugated to immunogold particles (12-nm diameter) revealed that GPI-hCAR was predominately localized to the cilial
shafts of ciliated cells (i, arrows), with less localization to the microvillus structures on ciliated cells (ii, arrowheads). HAE inoculated with AdVGFP
or a vehicle control alone and probed with RmcB showed no immunogold labeling. Bar 
 1 m.
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fer equally in nonpolarized cell lines (27, 34, 37), our data
support the hypothesis that an extracellular barrier on the
apical surface of HAE restricts AdV access to GPI-hCAR.
Identification of glycoconjugates on the HAE apical surface.
To identify components of the HAE surface glycocalyx, we
probed the apical surface with lectins and antibodies for spe-
cific glycoconjugates (Fig. 3). These data revealed that the
apical surface of HAE is rich in 2-6-linked sialic acid residues
(SNA probe) (Fig. 3, panel i) but not 2-3-linked sialic acid
residues (MAL II probe) (Fig. 3, panel ii). The predominance
of the 2-6 linkage of sialic acid on HAE is consistent with the
large numbers of ciliated cells and the previous localization of
this linkage to ciliated cell surfaces (3). The highly sialylated,
O-glycosylated tethered mucin MUC1 was also abundant on
the apical surface of HAE, as shown by use of a well-charac-
terized MUC 1 antibody (b2729) (8, 9) (Fig. 3, panel iii).
Glycocalyx structures also often contain proteoglycans, the
presence of which was evaluated by the use of antibodies for
specific glycosaminoglycan chains. Keratan sulfate (KS) was
detected at the apical surface of HAE, but only on subpopu-
lations of cells (Fig. 3, panel iv). Members of our laboratory
previously localized KS to the apical surfaces of ciliated cells in
HAE (48). Immunoreactivity for heparan sulfate (Fig. 3, panel
v), chondroitin-4- and -6-sulfate, and dermatan sulfate was not
detected on the apical surface of HAE.
Disruption of apical surface glycocalyx structure as a strat-
egy to increase AdV-mediated gene transfer. The identification
of HAE glycocalyx components suggested strategies to elimi-
nate this barrier in an attempt to improve the accessibility of
AdV to GPI-hCAR. Preliminary experiments in which GPI-
hCAR was pretreated with a broad-spectrum NA (NA III from
Vibrio cholerae) did not enhance the AdV-mediated gene
transfer efficiency (results not shown), indicating that the api-
cal barrier on HAE did not solely involve sialic acid residues,
as was found for MDCK cells (27). This suggested that the
glycocalyx of HAE is more complex and/or more robust than
that of MDCK cells. We tested whether the KS-degrading
enzymes keratanase I and/or II could improve AdV-mediated
gene transfer to GPI-hCAR HAE cultures. Although KS was
efficiently cleaved from the apical surface (determined by the
loss of 5D4 antibody immunoreactivity), AdV-mediated gene
transfer was not enhanced (data not shown). Similarly, enzy-
matic reagents that specifically degraded heparan sulfate (he-
parinases), chondroitin sulfate (chondroitinase ABC), hyalu-
ronan (hyaluronidase), and glycoproteins (O-sialoglycoprotein
endopeptidase and elastase) all failed to improve gene transfer
efficiency to GPI-hCAR HAE (data not shown). In contrast,
the nonspecific protease XIV (PXIV) enhanced gene transfer
efficiency to GPI-hCAR HAE six- to eightfold compared with
that for HAE. PXIV pretreatment also resulted in a modest
(two- to threefold) increase in gene transfer to a HAE culture
that did not express GPI-hCAR (Fig. 4A).
Inhibitors of glycan synthesis were also tested to determine
if reduced glycosylation of the cell surface could enhance the
gene transfer efficiency. For these studies, HAE cultures were
maintained in the presence of N-butyldeoxynojirimycin (a gly-
cosphingolipid inhibitor), 1-deoxynojirimycin (an N-glycan
synthesis inhibitor), sodium chlorate (an inhibitor of sulfation),
or benzyl 2-acetamido-2-deoxy--D-galactopyranoside (a py-
FIG. 2. Inefficient AdV-mediated gene transfer to HAE in the
presence of apical GPI-hCAR. (A) Representative en face views of
control HAE (i and iii) and GPI-hCAR HAE (ii and iv) either probed
with anti-hCAR conjugated to Texas Red (i and ii) or monitored for
GFP expression 48 h after inoculation with AdVGFP (iii and iv).
Original magnification, 10. (B) Quantitative LacZ enzymatic analy-
ses of control HAE (hatched bars) or GPI-hCAR HAE (solid bars)
48 h after inoculation of the apical surfaces of the HAE cultures with
AdVLacZ at 2  1010 or 2  1011 particles/ml. The data represent 14
samples for each bar from cultures derived from four different patient
samples and are means  standard errors (SE).
FIG. 3. Immunodetection of glycoconjugates on the apical surfaces
of HAE cultures. Cultures were exposed to probes for the following:
(i) 2-6-linked sialic acid residues, (ii) 2-3-linked sialic acid residues,
(iii) MUC1 glycoprotein, (iv) keratan sulfate, and (v) heparan sulfate
or chondroitin sulfate. The probes were then detected with secondary
reagents conjugated to Cy3 or Texas Red. Secondary reagents in the
absence of specific probes showed no fluorescence on HAE (vi). Orig-
inal magnification, 10.
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ranoside [PYR] that is an O-glycan inhibitor) for 5 days prior
to the inoculation of HAE or GPI-hCAR HAE with AdV.
None of the reagents affected HAE morphology, the beating of
cilia, or the maintenance of an air-liquid interface during the 5
days of treatment. Of the reagents tested, only PYR modestly
increased AdV-mediated gene transfer efficiency (Fig. 4A),
suggesting that O-linked glycosylation provided at least a mi-
nor component of the apical surface barrier to AdV access.
Since we have hypothesized that the O-linked glycoproteins
contribute significantly to the glycocalyx barrier, we assessed
the effect of sequentially treating cultures with PYR for 5 days
and then exposing the apical surfaces of HAE to PXIV. This
strategy resulted in a synergistic improvement in AdV-medi-
ated gene transfer, with a 30-fold increase in gene transfer for
GPI-hCAR HAE compared to that achieved with untreated
HAE (Fig. 4A and B). In contrast, PYR and PXIV pretreat-
ment only modestly enhanced AdV-mediated gene transfer to
HAE (Fig. 4A and B). Confocal XZ optical sectioning of
GPI-hCAR HAE revealed that the GFP-positive cells were
columnar cells that were also positive for GPI-hCAR (Fig. 4C,
panel i). Ciliated, and to a lesser extent, nonciliated cell types
were targeted by AdVGFP (Fig. 4C, panel ii).
Since improvements in gene transfer to columnar cells may
also reflect a disruption of tight junctions, the transepithelial
resistance (TER) was measured as an index of tight junctional
permeability at the time of AdV inoculation. For both HAE
and GPI-hCAR HAE, TER was not significantly different for
cultures treated with PYR and PXIV versus vehicle controls
alone (Fig. 4D), and pretreatment did not reduce TER to lev-
els (30 to 50   cm2) that permit AdV to access endogenous
hCAR (16).
When combined, these data suggest that apical membrane
O-glycosylated protease-sensitive components of the human
airway glycocalyx account for at least a portion of the barrier
function against AdV accessing apical receptors. Although our
antibody data suggest that MUC1 is present in this barrier,
several other tethered mucins could account for this O-glyco-
sylated, protease-sensitive component of the glycocalyx. At the
FIG. 4. Enhancement of AdV-mediated gene transfer to GPI-hCAR HAE after elimination of apical surface glycocalyx. (A) Quantitative LacZ
enzyme analyses of AdV-mediated gene transfer 48 h after inoculation of HAE (hatched bars) or GPI-hCAR HAE (solid bars) either without
treatment (CTL; n 
 5 for each group) or after treatment of the apical surface with PXIV (0.01%; n 
 6), PYR (5 mM; n 
 8), or a combination
of both reagents (PYR  PXIV; n 
 5). Data represent means  SE for two different patient samples. (B) Representative en face images of HAE
(i and iii) and GPI-hCAR HAE (ii and iv) with no treatment (i and ii) and after apical surface treatment with a combination of PYR and PXIV
(iii and iv). Original magnification, 10. (C) Confocal XZ optical sectioning of GPI-hCAR HAE pretreated with PYR and PXIV, inoculated with
AdVGFP, and assessed for GFP expression 48 h later. Colocalization with anti-hCAR conjugated to Texas Red (i) or anti--tubulin IV conjugated
to Texas Red (ii) revealed that GFP-expressing cells also expressed GPI-hCAR and were predominately ciliated. The rare occurrence of GPI-
hCAR-negative cells that were positive for GFP most likely reflected the absence of GPI-hCAR detection within the optical plane analyzed.
Nonciliated cells were also occasionally positive for GFP expression (ii, arrows). Original magnification, 63. (D) Effect of PYR and PXIV
treatment on the TERs of HAE (hatched bars) and GPI-hCAR HAE (solid bars). Data represent means  SE for at least five cultures from two
different patient samples.
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present time, there are eight reported tethered mucins whose
expression and function in the airway have not yet been de-
fined. Using RT-PCR, we determined that the tethered mucin
species MUC1, MUC4, MUC13, MUC15, and MUC16 are
expressed in HAE, with no evidence for the expression of
MUC12 and MUC17 (Fig. 5). At present, the contribution of
each of the expressed mucin species to a glycocalyx barrier to
AdV is unknown.
Comparison of glycocalyx abundance on human airway ep-
ithelium in vitro and in vivo. Although HAE cultures preserve
many of the phenotypic characteristics of the human airway
epithelium in vivo, i.e., ciliated and mucous cell differentiation,
ion transport capacities, mucus secretion, and mucociliary trans-
port (23, 24, 31), it is unknown whether the mass of glycocalyx
on HAE in vitro reflects that present on the human tracheo-
bronchial epithelium in vivo. Therefore, we compared the rel-
ative amounts of glycocalyx on HAE cultures to those on
freshly excised human tracheobronchial airway specimens.
Since glycocalyx composition and quantity may differ among
individual donors, we assessed the glycocalyxes in freshly ex-
cised tracheobronchial tissue and HAE generated from cells
derived from the same donor. In preliminary experiments, we
determined that standard preparation techniques for TEM
resulted in dehydration of the samples, producing a significant
loss and/or collapse of the glycocalyx carbohydrate structure.
As an alternative, we used the freeze substitution technique,
which better preserves the hydrated form of the glycocalyx
structure (20). Representative TEM photomicrographs of cil-
iated and mucus cell apical surface glycocalyxes on HAE and
freshly excised tissues derived from the same donor after
freeze substitution are shown in Fig. 6. With this technique,
glycocalyxes were visualized as abundant masses on the apical
surfaces of ciliated and nonciliated cell types and were pre-
dominately localized on microvilli. The combination of the
extended structure of the microvillar processes and the glyco-
calyx present on the microvilli provided an effective barrier
depth of approximately 3 to 4 m, i.e., 50% of the length of
a fully extended cilium. Although the overall depth of the
glycocalyx layer on HAE was similar to that observed on
freshly excised tissue, the increased density of web- or matrix-
like structures on freshly excised tissues suggested that the
glycocalyx was more abundant in vivo. Thus, in vitro results
seem likely to underestimate the contribution of the glycocalyx
as a barrier to gene transfer.
Generation of in vivo model to evaluate AdV gene transfer to
airway epithelium. To determine the influence of an in vivo
glycocalyx barrier to AdV-mediated gene transfer, we gener-
ated a transgenic mouse model with GPI-hCAR expression
specifically in epithelial cells. RT-PCRs to amplify tethered
mucins from tracheal and lung samples of mice suggested that,
as for humans, the mouse glycocalyx contains a variety of
O-glycosylated high-molecular-weight proteins that may con-
tribute to a barrier function (Fig. 7). The tethered mucins
Muc1, Muc4, Muc13, and Muc16 were expressed in murine
trachea and lung samples, consistent with the presence of these
mucins in HAE. Sequences for the mouse homologues of
MUC12, -15, and -17 are currently unavailable, so the expres-
sion of these mucins could not be determined. Nonetheless,
the tethered mucins are likely important components of both
human airway and murine airway epithelial glycocalyxes, sug-
gesting that the murine tracheal epithelium provides a reason-
able in vivo model to test our hypothesis that the glycocalyx
provides a barrier to efficient gene transfer by restricting the
access of AdV to receptors located on the apical surface. To
develop our in vivo model, we generated transgenic mice ex-
pressing GPI-hCAR selectively in epithelial cells by using the
epithelial cell-specific K18 promoter.
To determine whether the transgenic expression of GPI-
hCAR led to apical surface localization in vivo, we probed
airway regions from both transgenic and littermate control
mice with a human CAR antibody (RmcB). All regions of
transgenic mouse airways (nasal, tracheal, bronchial, and bron-
chiolar regions) were positive for GPI-hCAR. We detected
GPI-hCAR expression throughout the airways of four different
founder lines, although the expression levels were not consis-
tent between lines. For further study, we chose a founder line
that gave robust and consistent expression of GPI-hCAR in the
airway epithelium. Figure 8 shows representative sections from
transgenic murine nasal and lower airway epithelia displaying
GPI-CAR expression predominately on the apical surfaces of
the epithelia. RmcB immunoreactivity was not detected in any
region of the airway epithelium derived from littermate con-
trols. The submucosal glands of the murine nasal and tracheal
epithelia were also positive for GPI-hCAR expression (Fig. 8,
panel i). No RmcB immunoreactivity was detected in the al-
veolar regions (not shown).
In order to extend the model, we used the availability of
Muc1 knockout mice (Muc1/) to test the effect of removing
FIG. 5. RT-PCR analyses of human tethered mucin genes (MUC)
in human placental (Plac), colon (Col), bronchial epithelial (HBE),
and nasal epithelial (HNE) cells.  and , RT-PCRs performed in the
presence and absence, respectively, of reverse transcriptase.
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Muc1 on the AdV gene transfer efficiency in vivo. GPI-hCAR
transgenic mice were bred to express GPI-hCAR with or with-
out Muc1 and were maintained with homozygosity for Muc1
(/ or /) and heterozygosity at the transgenic GPI-hCAR
locus. As described above, GPI-hCAR was localized to the
apical surface of the tracheal epithelium in GPI-hCAR trans-
genics (Fig. 9A, panel i) but not in littermate controls (Fig. 9A,
panel ii). In transgenic murine tracheas displaying GPI-CAR
expression at the apical surface of the epithelium, Muc1 was
localized to the tracheal epithelium, as visualized with an
antibody (CT2) generated against the C-terminal domain of
murine Muc1 (17). CT2 immunoreactivity was detected on
the apical surface of the tracheal epithelium in GPI-hCAR/
Muc1/ mice but not GPI-hCAR/Muc1/ mice (Fig. 9A,
panels iv and vi, respectively). For Muc1/ mice, CT2
immunoreactivity colocalized with RmcB immunoreactivity.
Tracheal submucosal glands were the only airway regions
that were positive for GPI-hCAR but not for Muc1 in GPI-
hCAR/Muc1/ mice (results not shown). In contrast, for
GPI-hCAR/Muc1/ transgenics, Muc1 expression but not
GPI-hCAR expression was detected in type II alveolar epithe-
lial cells (results not shown). With RmcB conjugated to immu-
nogold particles, GPI-hCAR expression in the transgenic mu-
rine tracheal epithelium was localized to the apical surfaces of
both ciliated and Clara cells (Fig. 9B). The distribution of GPI-
hCAR to the cilial shafts and, to a lesser extent, the microvilli
of murine ciliated cells resembled the distribution of GPI-
hCAR in HAE in vitro.
Intralumenal delivery of AdV to murine tracheal epithelium
in vivo. Since the controlled delivery of viral vectors to defined
regions of the murine lung in vivo is difficult, we delivered AdV
to the tracheal airway epithelium by using a previously de-
scribed double-tracheostomy method (26). Representative en
face images of tracheal epithelia from Muc1/, GPI-hCAR/
Muc1/, Muc1/, and GPI-hCAR/Muc1/ mice inocu-
lated with AdLacZ and processed for the visualization of LacZ
expression 48 h later are shown in Fig. 10A. The inoculation of
Muc1/ (Fig. 10A, panel i) and GPI-CAR/Muc1/ (Fig.
10A, panel ii) tracheal epithelia with AdVLacZ (1011 particles/
ml, 20 l for 0.5 h) resulted in few positive epithelial cells, with
most positive regions being areas of epithelial injury secondary
to surgery. In contrast, the inoculation of Muc1/ (Fig. 10A,
panel iii) and GPI-hCAR/Muc1/ (Fig. 10A, panel iv) tra-
cheas with AdV resulted in enhanced gene transfer. Longitu-
FIG. 6. Assessment of glycocalyx abundance on the surfaces of human airway epithelia in vitro and ex vivo by freeze substitution and
transmission electron microscopy of HAE cultures (i and iii) and freshly excised human airway epithelium (ii and iv). Representative regions of
the apical surfaces of ciliated cells (i and ii) and nonciliated cells that possess microvillus structures but not cilia are shown (iii and iv). Bar 
 1 m.
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dinal histological cross sections of representative tissues from
each group of animals revealed that ciliated and nonciliated
cell types expressed LacZ in GPI-hCAR/Muc1/ mice (Fig.
10A, panels v and vi). Quantitative analyses revealed that non-
transgenic Muc1/ control animals expressed LacZ in 1.6%
 0.2% (range, 0.1 to 6.0%; n 
 30) of the tracheal epithelial
surface area, whereas GPI-hCAR/Muc1/ mice expressed
LacZ in 1.7%  0.3% (range, 0.0 to 6.0%; n 
 30) of the
tracheal epithelial surface area (Fig. 10B). These values were
not statistically different, suggesting that the expression of an
apical receptor in the tracheal epithelium in vivo was not suf-
ficient to enhance AdV-mediated gene transfer.
However, there was an increase in gene transfer efficiency
for mice in the Muc1/ background for both nontransgenic
and GPI-hCAR-positive animals. Quantitative image analyses
(Fig. 10B) revealed that for Muc1/ mice, AdV-mediated
gene transfer increased to 4.9%  0.6% (range, 3.0 to 6.6%; n

 7) of the tracheal epithelial surface area. The presence of
GPI-hCAR in Muc1/ mice led to gene transfer in 7.9% 
FIG. 7. RT-PCR analyses of murine tethered mucin genes (Muc)
in the murine colon (Col), murine trachea (Trach), or murine whole
lung (Lung).  and , RT-PCRs performed in the presence and
absence, respectively, of reverse transcriptase.
FIG. 8. Localization of RmcB immunoreactivity in the murine air-
way epithelium of K18-GPI-hCAR transgenic mice. Representative histo-
logical sections from murine nasal epithelia (i and ii) or small airway ep-
ithelia (iii and iv) derived from transgenics (i and iii) or littermate controls
(ii and iv) and probed with RmcB and secondary antibodies conjugated
to fluorescein isothiocyanate (green) are shown. Note that RmcB immu-
noreactivity below the surface of the nasal epithelium occurred in re-
gions associated with glandular structures. Original magnification, 100.
FIG. 9. Expression of GPI-hCAR and Muc1 glycoprotein at the
apical surfaces of murine tracheal epithelia derived from GPI-hCAR
transgenic mice. (A) Immunolocalization of GPI-hCAR (green) to the
apical surfaces of murine tracheas derived from K18-GPI-hCAR trans-
genics (i) but not littermate controls (ii). The colocalization of GPI-
hCAR (iii, green) and Muc1 (iv, red) in GPI-hCAR/Muc1/ trans-
genic animals and the presence of GPI-hCAR (v, green) but not Muc1
(vi, red) at the apical surfaces of murine tracheal epithelia from GPI-
hCAR/Muc1/ animals are shown. Bar 
 20 m. (B) Electron mi-
crographs of GPI-hCAR-expressing murine tracheal epithelium
probed with anti-hCAR and detected with anti-mouse IgG conjugated
to immunogold particles (12-nm diameter). Immunogold was detected
on the cilial shafts of ciliated cells (arrows) and the apical surfaces of
Clara cells (arrowheads). Similar procedures performed with a litter-
mate control tracheal epithelium revealed no immunogold localiza-
tion. Bar 
 500 nm.
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FIG. 10. AdV-mediated gene transfer to murine tracheal epithelium is enhanced by GPI-hCAR only in the absence of Muc1 glycoprotein from
the lumenal surface. (A) Representative photomicrographs of excised murine tracheas displaying LacZ expression in the surface epithelium.
Tracheal epithelia from control (i), GPI-hCAR transgenic (ii), Muc1/ knockout (iii), and GPI-hCAR/Muc1/ (iv) animals were inoculated with
AdVLacZ (20 l at 1011 particles/ml) and assessed 48 h later for gene transfer. Histological sections of murine tracheal epithelia from
GPI-hCAR/Muc1/ animals revealed that airway surface epithelial cells expressed the transgene, with both ciliated cells (v, arrows) and Clara
cells (vi, arrows) being transduced by AdVLacZ. (B) Quantitative morphological analyses of the percentages of epithelial surface area exposed to
AdVLacZ that expressed LacZ after 48 h for tracheas derived from Muc1/ (n 
 30), GPI-hCAR/Muc1/ (n 
 30), Muc1/ (n 
 7), and
GPI-hCAR/Muc1/ (n 
 22) animals. For comparison, the percentage of epithelial surface area expressing LacZ after sodium caprate treatment
(25 mM) prior to AdVLacZ inoculation is shown (n 
 12). Data represent means  SE.  and , statistically significant differences, with P 	
0.0002 and P 	 0.02, respectively.
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0.6% (range, 3.1 to 13.4%; n 
 22) of the tracheal epithelial
surface area. For comparison, AdV-mediated gene transfer
immediately after tight junction disruption by a sodium caprate
pretreatment (25 mM) resulted in 15.5%  1.8% (range, 7.1 to
23.6%; n 
 12) of the tracheal epithelial surface area express-
ing LacZ. The percentages of tracheal epithelium that were
transduced by AdVLacZ after sodium caprate pretreatment
were not different when tracheas from control or GPI-CAR
transgenic animals were used (not shown). Whether sodium
caprate-facilitated gene transfer represents a maximum level of
gene transfer efficiency with sodium caprate in this model or
whether the efficiency of tight junctional disruption in vivo was
significantly less than that achieved with sodium caprate in
vitro remains to be determined.
These data suggest that Muc1 is one component of the
murine tracheal epithelium glycocalyx that inhibits gene trans-
fer. However, this molecule is not solely responsible for the
barrier function of the glycocalyx, since AdV did not transduce
all surface epithelial cells in the absence of Muc1.
Murine glycocalyx and the contribution of tethered Muc1 to
this layer. Detection of the carbohydrate mass on the murine
tracheal epithelium with ruthenium red revealed that both
ciliated and nonciliated (Clara) cell types possessed an abun-
dant apical surface glycocalyx (Fig. 11A). In addition to the
microvillus surfaces being covered with the glycocalyx, the cilial
shafts were also associated with significant ruthenium red
staining, suggesting that a cilial glycocalyx layer may also func-
tion as a barrier to restrict AdV access to these regions. Fur-
ther examination of the cilial shaft carbohydrate layer revealed
that the glycocalyx was uniformly distributed along the shaft,
with an estimated glycocalyx depth of 50 nm. This measured
depth is likely an underestimate since after TEM preparation
the glycocalyx layer was significantly dehydrated and con-
densed with ruthenium red.
To estimate the contribution of Muc1 to this murine tracheal
epithelium glycocalyx layer, we assessed the depths of the
carbohydrate layers on tracheal epithelial cell surfaces of
Muc1/ and Muc1/ mice by morphological analyses of the
depth of ruthenium red staining (Fig. 11B). These data showed
that the glycocalyx depth on the apical surfaces of nonciliated
cells, but not on ciliated cells, was significantly reduced for
Muc1/ mice compared to the case for Muc1/ mice. How-
ever, although differences in the overall glycocalyx depth were
detected for Muc1/ mice, the differences in depth repre-
sented only a fraction of the total depth. This finding suggests
that although Muc1 is a component of the airway glycocalyx,
other glycoconjugates contribute to this structure and the loss
of a single mucin species will not dramatically alter the glyco-
calyx depth. The presence of other large, heavily glycosylated
mucin species, as detected by RT-PCR, may account for the
barrier function of the glycocalyx in the absence of MUC1/
Muc1.
DISCUSSION
Studies of inefficient AdV-mediated gene transfer to the
lumenal surfaces of well-differentiated human airway epithelial
cells have previously focused on the absence of lumenal sur-
face receptors that are required for AdV attachment and entry
(CAR and V integrins) (28, 36, 47). These observations have
led to strategies to retarget viral vectors to other apically lo-
cated receptors that are competent for viral entry into the cell.
By redirecting hCAR expression to the apical surfaces of the
human tracheobronchial respiratory epithelium in vitro and
the murine tracheal respiratory epithelium in vivo, we have
tested the strategy of retargeting AdV to receptors on the
lumenal surface and have shown that components of the airway
surface glycocalyx restrict the access of AdV to these apical
receptors. We have determined that O-glycosylated glycopro-
tein components of the airway glycocalyx, most likely tethered
mucins such as MUC1, are major contributors to the barrier
function of the glycocalyx structure. These findings suggest that
strategies to retarget AdV to alternate receptor types present
on the airway epithelial surface without methods to circumvent
the glycocalyx barrier will have limited success. These obser-
vations may also have implications for AdV-mediated gene
transfer strategies for cancer treatments since many epithelial
cell cancers have been shown to overexpress tethered mucins
on the cell surface, e.g., MUC1 in breast cancer (40), MUC4 in
pancreatic cancer (2) and MUC16 in ovarian cancer (44).
The overall efficiency of gene transfer to HAE in vitro re-
FIG. 11. Assessment of glycocalyx depth on the apical surface of
murine tracheal epithelium in the presence and absence of Muc1 gly-
coprotein. (A) Representative transmission electron micrograph of
murine tracheal epithelium stained with ruthenium red to assess the
abundance of glycoconjugates. Ruthenium red staining on the apical
surfaces of ciliated cells (CC) and nonciliated cells (Clara cell; NCC)
is shown. Bar 
 2 m. (B) Quantitative morphological analyses of the
depths of ruthenium red staining on the surfaces of ciliated cells (CC),
nonciliated cells (NCC), or all cells (AC) of trachea epithelia derived
from Muc1/ (solid bars) and Muc1/ (open bars) mice. The data
shown represent means  SE. , statistically significant difference, with
P 	 0.05.
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mained low, with 2 to 3% of cells being transduced by
AdVGFP, despite the expression of a competent receptor at
the apical surface (Fig. 2). In terms of CF lung disease appli-
cations, correction of the cyclic AMP-mediated chloride secre-
tory response may require the expression of CFTR in 10% of
lumenal cells, whereas for sodium hyperabsorption correction,
80% of the cells must be transduced with CFTR (6). There-
fore, to reach these levels with AdV, we must achieve improve-
ments in gene transfer efficiency. Elimination of the glycocalyx
barrier by the use of inhibitors of O-glycosylation and a non-
specific protease may provide a sufficient gene transfer effi-
ciency for HAE in vitro; however, it is unlikely that sufficient
elimination of the glycocalyx can be achieved to increase the
gene transfer efficiency with retargeted AdV in vivo.
Compared to HAE in vitro, freshly excised human airway
tissue also possessed a robust glycocalyx, suggesting that the
restriction of AdV access would also be observed with human
airways in vivo (Fig. 6). This was tested functionally with GPI-
hCAR mouse tracheal epithelium in vivo, which confirmed
that a glycocalyx barrier restricted AdV gene transfer in vivo
(Fig. 10). Although it is difficult to directly compare the HAE
model and the murine tracheal model since GPI-hCAR may be
expressed at different levels in the two models and since human
adenoviruses may not replicate as efficiently in murine airway
cells as they do in human airway cells, these observations do
suggest that the glycocalyx structure and abundance in vivo
may provide a larger barrier to AdV than the glycocalyx layer
of HAE cultures in vitro. This conclusion predicts that efforts
to eliminate the glycocalyx layer in vivo by enzymatic means
may be insufficient to improve the AdV-mediated gene trans-
fer efficiency. Furthermore, inhibitors of O-glycosylation that
are useful for in vivo delivery are not yet available.
The human airway glycocalyx is complex, with the large
O-glycosylated mucin glycoproteins being a major component.
The human airway epithelium expresses multiple mucin mol-
ecules, some of which are secreted mucins (e.g., MUC5AC and
MUC5B), while others are tethered to the apical surface of
the airway (e.g., MUC1 and MUC4). Given that MUC4 and
MUC16 appear to be relatively highly expressed and that they
are both large, heavily glycosylated tethered mucins (1
MDa), it seems reasonable to speculate that these mucins, in
addition to MUC1, have important barrier functions against
infection of the airway epithelium by viruses such as AdV. The
identification of MUC1 on the apical surface of HAE sug-
gested that MUC1 is an important tethered mucin in HAE
(Fig. 3). Strategies to specifically reduce the MUC1 abundance
on HAE in vitro are not yet feasible, but the availability of a
Muc1/ mouse model allowed us to test the implications
of removing Muc1 from the tracheal epithelium in vivo. The
modest increase in AdV-mediated gene transfer observed in
GPI-hCAR/Muc1/ mice compared to nontransgenic Muc1/
mice suggested a role for Muc1 in restricting AdV access. A
surprising finding was the enhanced gene transfer observed in
vivo for mouse tracheal epithelium that was devoid of both
Muc1 and GPI-hCAR expression. These data suggest that the
absence of Muc1 allowed gene transfer via a CAR-indepen-
dent pathway, assuming that tight junctional integrity was not
altered in the Muc1/ mice. These observations are consis-
tent with an earlier study in which the low level of CAR-
independent AdV-mediated gene transfer to polarized MDCK
cells was abolished by the transfection of MUC1 into these
cells (1).
We have shown that GPI-hCAR was expressed in both cil-
iated and nonciliated cell types in HAE in vitro and in the
mouse tracheal epithelium in vivo. Interestingly, GPI-hCAR
was expressed in the shafts of ciliated cells in both species.
These observations indicate that GPI-hCAR and possibly
other GPI-linked proteins may have a tendency to localize to
the cilial shaft membranes. Paramecium primary cilia contain
proteins that are exclusively GPI-linked, suggesting that GPI-
linked proteins favor the membrane environment of cilial
structures (10).
Our in vitro data for HAE contrast with the results of a
previous study that used a similar human airway epithelial cell
culture model expressing GPI-hCAR at the lumenal surface
(37). In the earlier report, apical GPI-hCAR expression was
sufficient to mediate gene transfer to HAE, and the access of
AdV to GPI-hCAR was unhindered by glycocalyx components.
In our study, the improvement in gene transfer efficiency was
low, with only 2 to 3% of GPI-hCAR-positive cells being trans-
duced by AdVGFP. Although the reasons for the differences
between these two studies are not immediately obvious, it is
possible that they are due to the different culture conditions
used for HAE. The cultures used for the present study were
maintained in tissue culture medium supplemented with bo-
vine pituitary gland extract, whereas in the previous study,
Walters et al. used UltraSer G as a serum substitute. Although
both culture conditions produce well-differentiated and cili-
ated HAE cultures, it is possible that the composition and/or
abundance of the glycocalyx differed between the two HAE
models. Interestingly, AdV has been shown to infect HeLa
cells more efficiently when they are grown in UltraSer G than
when they are grown in fetal bovine serum, an effect attributed
to the increased access of AdV to cell surface receptors by a
reduction in the steric hindrance of glycocalyx components (5).
Our in vivo observations with a murine tracheal epithelium
model also support our observations with HAE and indicate
that the AdV-mediated gene transfer efficiency was not in-
creased by GPI-hCAR expression. These data suggest that the
glycocalyx provided an absolute barrier to AdV in vivo and that
the in vitro HAE model may underestimate the restrictive
nature of the glycocalyx to AdV in vivo.
The largely negative results with glycocalyx-degrading en-
zymes in our study and the ineffectiveness of N- and O-gly-
canase in an earlier study (37) may reflect the fact that these
enzymes only affect specific carbohydrate linkages, leading to
fragmented digestion of the large, heavily glycosylated mole-
cules that remain restrictive to AdV. Indeed, our data indicate
that the removal of sugar residues per se may not be sufficient
to significantly improve gene transfer. The removal of protein-
aceous structures by proteases to cleave the major portion of
these molecules may be necessary to significantly improve gene
transfer.
The glycocalyx layer may restrict AdV access to the apical
surface by acting as a molecular sieve or by providing false
substrates for AdV attachment. In earlier work, members of
our laboratory used TEM to show that AdV was predomi-
nately associated with fine filamentous structures radiating
from microvillus structures on human airway epithelial cells
(28). These structures were likely components of the airway
13766 STONEBRAKER ET AL. J. VIROL.
glycocalyx. The fate of AdV attached to glycocalyx structures
on the HAE cultures was not determined in this study. How-
ever, it has been shown with the murine airway that early after
AdV administration to the lung, macrophages migrate to and
internalize AdV particles that are present in the airway lumen
attached to glycocalyx structures (49). It has been estimated
that 70 to 90% of AdV particles are sequestered by airway
macrophages 24 h after intralumenal administration to the
lung (41, 49). We predict that glycocalyx components present
AdV to incoming macrophages for phagocytosis and degrada-
tion. In addition to serving a presentation role, the tethered
mucins are shed from the airway surface and incorporated into
the soluble mucin layers (25). This feature raises the possibility
that AdV attached to shed tethered mucins may be eliminated
from airways by incorporation into the mucociliary transport
system.
The difficulties of delivering AdV to the lumenal surfaces of
human airways suggest that we consider other methods for
delivering genes to the lung. Other viruses are known to effi-
ciently infect the respiratory epithelium and have presumably
evolved strategies to circumvent the glycocalyx barrier. Human
coronaviruses, filoviruses, respiratory syncytial virus, and Sen-
dai virus have improved gene transfer capacities for the airway
epithelium after lumenal delivery compared to AdV (29, 38,
45, 48). Further studies of the interactions of these enveloped
viruses with the airway epithelium and a definition of how they
circumvent the glycocalyx barrier may reveal mechanisms that
will aid the development of improved vectors for the delivery
of therapeutic transgenes to the lung epithelium.
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